Hepatitis A clinical trials
The registry lists 82 studies for Hepatitis A across more than 10 countries. 9 are recruiting or about to start. 51 of them are mainly about Hepatitis A (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-22.
Get an email when these change. Save the Hepatitis A studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
GlaxoSmithKline (27) · Sinovac Biotech Co., Ltd (8) · Sanofi Pasteur, a Sanofi Company (6) · Crucell Holland BV (3) · Chiang Mai University (3) · China National Biotec Group Company Limited (2) · Assiut University (2) · Institute of Medical Biology, Chinese Academy of Medical Sciences (2)
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Nov 2026Study on the Long-Term Persistence of Immunity Induced by Inactivated Hepatitis A Vaccine · Sinovac Biotech Co., Ltd
- Dec 2026the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines · China National Biotec Group Company Limited
- Sep 2027Risk Factors and Outcomes of Hepatitis A in Children · Assiut University
Who these studies take
Of the 3 Hepatitis A studies recruiting now, 0 (0%) set no upper age limit and 3 (100%) stop at 75 or younger. 1 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (67%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (33%) | 1 (33%) |
| 18 | 2 (67%) | 2 (67%) |
| 30 | 2 (67%) | 2 (67%) |
| 40 | 2 (67%) | 2 (67%) |
| 50 | 2 (67%) | 2 (67%) |
| 65 | 2 (67%) | 2 (67%) |
| 75 | 1 (33%) | 1 (33%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 82 studies, recruiting or not: 72% stop at 75 or younger and 68% at 65; 67% take children; 2% are for women only and 1% for men only; 80% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
- Study on the Long-Term Persistence of Immunity Induced by Inactivated Hepatitis A VaccineOct 22, 2026NCT07889219
Studies
Recruiting first, then most recently updated. Showing 50 of 82. Browse all 82 → or search them.
- Study on the Long-Term Persistence of Immunity Induced by Inactivated Hepatitis A VaccineRecruitingNCT078892191 country
- Risk Factors and Outcomes of Hepatitis A in ChildrenNot yet recruitingNCT07848321
- Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral HepatitisNot yet recruitingNCT07525401Not applicable
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L VaccinesNot yet recruitingNCT073388511 country
- Immunity With Acute Hepatits ANot yet recruitingNCT06942962
- Phase IV Study of Concomitant Administration of the sIPV and HepANot yet recruitingNCT06460545Phase 41 country
- Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and CirrhosisRecruitingNCT06277882Phase 41 country
- Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination.Not yet recruitingNCT06184230Phase 4
- A Study to Evaluate the 17-Year Immune Persistence of a Single Dose of Inactivated Hepatitis A VaccineCompletedNCT078557051 country
- Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAVActive, not recruitingNCT06978621Phase 31 country
- Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021CompletedNCT049393501 country
- Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and AdolescentsActive, not recruitingNCT070326101 country
- Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected PeopleCompletedNCT06576024Phase 41 country
- Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and AdolescentsCompletedNCT06298708Phase 31 country
- Effects of Aging on Primary and Secondary Vaccine ResponsesCompletedNCT03312699Phase 11 country
- Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years OldActive, not recruitingNCT06058416Phase 41 country
- Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young ChildrenCompletedNCT00139113Phase 41 country
- Hepatitis B in Cystic Fibrosis and Latent Tuberculosis RespectivelyWithdrawnNCT02605538Not applicable1 country
- The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A VaccinesCompletedNCT01949857Phase 41 country
- Seroepidemiology of Viral Hepatitis in Hong KongCompletedNCT043712761 country
- Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected PatientsCompletedNCT03855176Phase 41 country
- To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrsStatus unknownNCT05613127Phase 32 countries
- What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 YearsCompletedNCT046383351 country
- A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis ACompletedNCT00139139Not applicable1 country
- Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B VaccineCompletedNCT02445703Phase 41 country
- Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A VaccineStatus unknownNCT03330171Phase 41 country
- Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B VaccCompletedNCT00289731Phase 43 countries
- Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A VaccineCompletedNCT00534885Phase 41 country
- Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With MenWithdrawnNCT03445416Not applicable
- Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in MexicoCompletedNCT021128901 country
- Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR VaccinesCompletedNCT01307436Phase 31 country
- Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)CompletedNCT00326183Phase 4
- Twinrix Pregnancy RegistryCompletedNCT03619590
- Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix AdultCompletedNCT01037114Phase 41 country
- Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix AdultCompletedNCT01000324Phase 41 country
- Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™CompletedNCT00875485Phase 42 countries
- Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were ComparedCompletedNCT00197184Phase 33 countries
- Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 MonthsCompletedNCT00197236Phase 31 country
- Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month ScheduleCompletedNCT00289744Phase 31 country
- Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary VaccinationCompletedNCT00684671Phase 42 countries
- Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy AdultsCompletedNCT00289770Phase 31 country
- Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of AgeCompletedNCT00197002Phase 31 country
- Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in ChildrenCompletedNCT00197015Phase 31 country
- Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month ScheduleCompletedNCT00289757Phase 41 country
- Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191CompletedNCT010867091 country
- Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in IsraelWithdrawnNCT03183492Phase 4
- Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month ScheduleCompletedNCT00289718Phase 31 country
- Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month ScheduleCompletedNCT00291876Phase 41 country
- Comparative Immunogenicity Study of Two Hepatitis A VaccinesStatus unknownNCT03231605Phase 41 country